Infliximab suppliers
Infliximab
- CAS:
- MF:
- MW:
- 0
Company Type
Properties
Safety Information
Use
The MAb infliximab (Remicade, chimeric) is produced fromcells that have been sensitized with human TNFα. The MAbis a chimeric human–mouse immunoglobulin. The constantregions are of human peptide sequence and the variable regionsare murine. The MAb is of type IgG1 κ.Infliximab is indicated for the treatment of moderately toseverely active Crohn disease to decrease signs and symptomsin patients who had an inadequate response to conventionaltreatments. Infliximab binds specifically to TNFα. Itneutralizes the biological activity of TNFα by binding withhigh affinity to soluble and transmembrane forms of theTNF. Infliximab destroys TNFα-producing cells. An additionalmechanism by which infliximab could work is asfollows: by inhibiting TNFα, pathways leading to IL-1 andIL-6 are inhibited. These interleukins are inflammatory cytokines.Inhibiting their production blocks some of theinflammation common to Crohn disease.
4 supplier list of "Infliximab"
- Product Name:Infliximab
- Company Type: Trader
- Country/Region: EUROPE
- Product Name:Infliximab
- Company Type: Trader
- Country/Region: EUROPE